Sorafenib (Bay 43-9006) is a multikinase inhibitor with urea-core structure providing nanomolar potency against Raf-1/B-Raf (6/22nM), VEGFR2/3 (90/15nM), PDGFRβ (20nM), FLT3 (57nM), and c-Kit (58nM). Induces autophagy, apoptosis, and ferroptosis with potent antitumor activity.
Usually ships within 24 hours.